Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: Journal of Medical Internet Research

Date Submitted: Jan 3, 2024
Date Accepted: Jul 16, 2024

The final, peer-reviewed published version of this preprint can be found here:

An Advanced Machine Learning Model for a Web-Based Artificial Intelligence–Based Clinical Decision Support System Application: Model Development and Validation Study

Lin TH, Chung HY, Jian MJ, Chang CK, Perng CL, Liao GS, Yu J, Dai MS, Shang HS, Yu CP

An Advanced Machine Learning Model for a Web-Based Artificial Intelligence–Based Clinical Decision Support System Application: Model Development and Validation Study

J Med Internet Res 2024;26:e56022

DOI: 10.2196/56022

PMID: 39231422

PMCID: 11411218

Bridging Technology and Healthcare: ChatGPT’s Role in Predictive Models for Breast Cancer Recurrence

  • Tai-Han Lin; 
  • Hsing-Yi Chung; 
  • Ming-Jr Jian; 
  • Chih-Kai Chang; 
  • Cherng-Lih Perng; 
  • Guo-Shiou Liao; 
  • Jyh‐Cherng Yu; 
  • Ming-Shen Dai; 
  • Hung-Sheng Shang; 
  • Cheng-Ping Yu

ABSTRACT

Background:

Breast cancer is a leading global health concern necessitating advancements in recurrence prediction and management. The development of an Artificial intelligence-based clinical decision support system (AI-CDSS) using ChatGPT addresses this need with the aim of enhancing both prediction accuracy and user accessibility.

Objective:

The primary objective of this study was to develop and validate an advanced machine-learning model for a web-based AI-CDSS application, leveraging the question-and-answer guidance capabilities of ChatGPT to enhance data preprocessing and model development, thereby improving the prediction of breast cancer recurrence.

Methods:

This study focused on developing an advanced machine-learning model by leveraging data from the Tri-Service General Hospital breast cancer registry of 3,577 patients (2004–2016). ChatGPT is integral to preprocessing and model development, aiding in hormone receptor categorization, age binning, and one-hot encoding. Techniques such as the synthetic minority oversampling technique (SMOTE) address the imbalance of datasets. Various algorithms, including light gradient-boosting machine (LGBM), Gradient Boosting, and Extreme Gradient Boosting (XGB), were employed, and their performance was evaluated using metrics such as the area under the curve (AUC), accuracy, sensitivity, and F1-score.

Results:

The LGBM model demonstrated superior performance, with an AUC of 0.80, followed closely by the Gradient Boosting and XGB models. The web interface of the AI-CDSS tool was effectively tested in clinical decision-making scenarios, proving its utility in personalized treatment planning and patient involvement.

Conclusions:

The AI-CDSS tool, enhanced by ChatGPT, marks a significant advancement in breast cancer recurrence prediction, offering a more individualized and accessible approach for clinicians and patients. Although promising, further validation in diverse clinical settings is recommended to confirm its efficacy and expand its utility.


 Citation

Please cite as:

Lin TH, Chung HY, Jian MJ, Chang CK, Perng CL, Liao GS, Yu J, Dai MS, Shang HS, Yu CP

An Advanced Machine Learning Model for a Web-Based Artificial Intelligence–Based Clinical Decision Support System Application: Model Development and Validation Study

J Med Internet Res 2024;26:e56022

DOI: 10.2196/56022

PMID: 39231422

PMCID: 11411218

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.